130 related articles for article (PubMed ID: 34783047)
1. M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect.
Li B; Su L; Ye Y; Yan F
Stat Med; 2022 Feb; 41(4):815-830. PubMed ID: 34783047
[TBL] [Abstract][Full Text] [Related]
2. A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect.
Li B; Su L; Gao J; Jiang L; Yan F
Stat Methods Med Res; 2021 Mar; 30(3):904-915. PubMed ID: 33357047
[TBL] [Abstract][Full Text] [Related]
3. Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect.
Li B; Zhang J; Yang W; Su L; Yan F
Pharm Stat; 2024; 23(1):107-133. PubMed ID: 37859531
[TBL] [Abstract][Full Text] [Related]
4. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
5. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
6. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
7. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
Wu J; Zhu L; Li Y
J Biopharm Stat; 2023 Dec; ():1-14. PubMed ID: 38146192
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
Wu J; Wei J
Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
[TBL] [Abstract][Full Text] [Related]
9. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
Yu C; Huang X; Nian H; He P
Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Wei J; Wu J
Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
[TBL] [Abstract][Full Text] [Related]
11. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
12. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
Kim K; Boucher H; Tsiatis AA
Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
[TBL] [Abstract][Full Text] [Related]
13. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
Ding X; Wu J
Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
[TBL] [Abstract][Full Text] [Related]
14. Adaptive promising zone design for cancer immunotherapy with heterogeneous delayed treatment effect.
Li B; Yan F; Jiang D
J Biopharm Stat; 2024 Apr; ():1-20. PubMed ID: 38615361
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
16. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
17. Complex survival trial design by the product integration method.
Tang Y
Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
[TBL] [Abstract][Full Text] [Related]
18. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
19. Designing cancer immunotherapy trials with random treatment time-lag effect.
Xu Z; Park Y; Zhen B; Zhu B
Stat Med; 2018 Dec; 37(30):4589-4609. PubMed ID: 30203592
[TBL] [Abstract][Full Text] [Related]
20. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
